GlassScriptPhysician profile
Wael Mctabi
NPI 1144269093
$4,025.82
in general payments reported to CMS, 2019-2025
36 companies · $621 in 2025
The $621 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $435 · 2021: $542 · 2022: $706 · 2023: $639 · 2024: $772 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,031.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $532.24 | 2019-2025 | |
| Lilly USA, LLC | $468.28 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Astrazeneca Pharmaceuticals LP | $410.24 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Glaxosmithkline, LLC. | $325.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $303.51 | 2020-2022 | |
| Amgen INC. | $258.87 | 2019-2025 | Repatha, Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.89 | 2019-2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $191.18 | 2019-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $186.32 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.43 | 2019-2024 | Jardiance, Synjardy |
| Astellas Pharma US INC | $139.38 | 2019-2021 | |
| Abbvie INC. | $99.37 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.15 | 2021-2023 | |
| Abbott Laboratories | $71.99 | 2019-2025 | Proclaim, Eterna, Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $49.51 | 2024-2025 | Inspire |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $48.14 | 2019-2023 | |
| Esperion Therapeutics, INC. | $46.68 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.02 | 2022 | |
| Allergan, INC. | $36.56 | 2019-2020 | |
| Echosens North America, INC. | $32.91 | 2025 | Fibroscan |
| Dexcom, INC. | $26.23 | 2021 | |
| Medtronic, INC. | $24.39 | 2024 | Venaseal |
| Si-Bone, INC. | $23.96 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $22.96 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.68 | 2023 | |
| Sanofi Pasteur INC. | $21.04 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $19.96 | 2021 | |
| Redhill Biopharma INC. | $18.44 | 2020 | |
| Advanced Respiratory, INC | $18.06 | 2020 | |
| Merck Sharp & Dohme LLC | $17.85 | 2020 | |
| Linus Health, INC. | $16.87 | 2023 | |
| Xeris Pharmaceuticals, INC. | $16.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.70 | 2019 | |
| Exact Sciences Corporation | $14.07 | 2025 | The Cologuard Plus Collection Kit |
| Orthogenrx INC. | $12.90 | 2020 | |
| Hikma Pharmaceuticals USA | $12.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wael Mctabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.